Abstract: A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.
Type:
Grant
Filed:
June 20, 2014
Date of Patent:
September 6, 2016
Assignees:
The Trustees of the University of Pennsylvania, University of Florida Research Foundation, Incorporated, Cornell Research Foundation, Inc.
Inventors:
Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire
Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.
Type:
Application
Filed:
April 20, 2016
Publication date:
August 4, 2016
Applicants:
U.S. Government represented by the Department of V eterans Affairs, The Regents of the University of California, Cornell Research Foundation, Inc., Fundação Oswaldo Cruz - FIOCRUZ
Inventors:
Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
Abstract: The present invention relates to compositions and methods for displaying proteins and polypeptides on the surface of cells and cellular vesicles. Methods and compositions for drug and vaccine delivery using cell surface display systems of the present invention are also disclosed.
Type:
Grant
Filed:
May 4, 2015
Date of Patent:
July 19, 2016
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Matthew DeLisa, Jae-Young Kim, David A. Putnam, Anne M. Doody
Abstract: The invention relates to methods of preventing or inhibiting the onset and/or treating autoimmune demyelinating neuropathy and other autoimmune or inflammatory diseases involving macrophage infiltration.
Abstract: The present invention relates to an isolated DNA molecule encoding a fagopyritol synthase. A method for producing a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor is also described. The method includes providing a fagopyritol synthase, providing a substrate comprising a galactosy donor and a galactosy acceptor, and combining the fagopyritol synthase with the substrate under conditions effective produce a fagopyritol, an insulin mediator, an insulin mediator analogue, an insulin mediator homologue, or an insulin mediator inhibitor.
Abstract: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types.
Type:
Grant
Filed:
June 19, 2012
Date of Patent:
June 21, 2016
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Steven A. Goldman, Neeta Singh Roy, Martha Windrem
Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.
Type:
Grant
Filed:
October 6, 2015
Date of Patent:
June 14, 2016
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Yung-Fu Chang, Raghavan U. M. Palaniappan
Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.
Type:
Grant
Filed:
August 5, 2015
Date of Patent:
May 24, 2016
Assignees:
Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs, Fundação Oswaldo Cruz—FIOCRUZ
Inventors:
Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
Type:
Grant
Filed:
April 19, 2011
Date of Patent:
May 24, 2016
Assignees:
University of Florida Research Foundation, Inc., The United States of America as represented by The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention, Cornell Research Foundation, Inc.
Inventors:
Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, William L. Castleman, Nancy J. Cox
Abstract: The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurodegenerative disease or condition, stroke or trauma of the nervous system. In yet another aspect, the invention provides methods for promoting regeneration of a neural cell in a human in need thereof.
Type:
Grant
Filed:
March 9, 2012
Date of Patent:
May 24, 2016
Assignees:
Cornell Research Foundation, Inc., The Research Foundation of the City University of New York
Abstract: The present invention is directed to a method of designing a plurality of capture oligonucleotide probes for use on a support to which complementary oligonucleotide probes will hybridize with little mismatch, where the plural capture oligonucleotide probes have melting temperatures within a narrow range. The present invention further relates to an oligonucleotide array comprising of a support with the plurality of oligonucleotide probes immobilized on the support, a method of using the support to detect single-base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences, and a kit for such detection, which includes the support on which the oligonucleotides have been immobilized.
Type:
Grant
Filed:
July 22, 2013
Date of Patent:
May 17, 2016
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Francis Barany, Monib Zirvi, Norman P. Gerry, Reyna Favis, Richard Kliman
Abstract: The present invention relates to a method for diagnosing a subject's Alzheimer's disease state. The method involves providing a database containing information relating to protein expression levels associated and not associated with Alzheimer's disease. The database includes information relating to at least a majority of the following proteins: albumin, alpha-1-antitrypsin, apolipoprotin E, apolipoprotein J, complement component 3, contactin, fibrin beta, Ig heavy chain, Ig light chain, neuronal pentraxin receptor, plasminogen, proSAAS, retinol-binding protein, transthyretin, and vitamin D binding protein. Information relating to proteins found in one or more cerebrospinal fluid samples from a subject is also provided and a database is used to analyze the information from the subject to diagnose the subject's Alzheimer's disease state. Also disclosed is a computer readable medium and a system, both useful in carrying out the present invention.
Type:
Grant
Filed:
April 10, 2006
Date of Patent:
May 10, 2016
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Kelvin H. Lee, Norman R. Relkin, Erin Finehout
Abstract: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.
Type:
Grant
Filed:
March 16, 2012
Date of Patent:
April 19, 2016
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Hazel Szeto, Kesheng Zhao, Hugh Robertson, Alex V. Birk
Abstract: A cell culture method using an in vitro microscale cell culture device having a first microscale chamber containing cells attached to an inner surface of the chamber and cell culture medium in contact with the cells. The cells are maintained in culture in the in vitro microscale cell culture device while flowing culture medium through the first chamber at a controlled rate to provide a liquid residence time value for the cells in the first chamber of the in vitro microscale cell culture device that is comparable to a liquid residence time value obtained with respect to comparable cells in vivo, such that metabolism by the cells in culture in the in vitro microscale cell culture device is comparable to metabolism by comparable cells in vivo.
Type:
Grant
Filed:
November 21, 2011
Date of Patent:
March 1, 2016
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Michael Shuler, Gregory T. Baxter, Aaron Sin, Robert Andrew Harrison, Scott Meyers
Abstract: The present invention relates to an article fabrication system having a plurality of material deposition tools containing one or more materials useful in fabricating the article, and a material deposition device having a tool interface for receiving one of the material deposition tools. A system controller is operably connected to the material deposition device to control operation of the material deposition device. Also disclosed is a method of fabricating an article using the system of the invention and a method of fabricating a living three-dimensional structure.
Type:
Grant
Filed:
October 1, 2014
Date of Patent:
January 26, 2016
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Lawrence Bonassar, Hod Lipson, Daniel L. Cohen, Evan Malone
Abstract: The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support.
Type:
Grant
Filed:
December 9, 2013
Date of Patent:
January 12, 2016
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Francis Barany, George Barany, Robert P. Hammer, Maria Kempe, Herman Blok, Monib Zirvi
Abstract: The present invention relates to methods of using cocaine-binding-site ligands and cocaine-binding-site RNA aptamers to treat or prevent Alzheimer's Disease and to reduce or prevent aggregation of beta-amyloid peptides in a subject.
Abstract: The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support.
Type:
Grant
Filed:
October 14, 2014
Date of Patent:
December 8, 2015
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Francis Barany, George Barany, Robert P. Hammer, Maria Kempe, Herman Blok, Monib Zirvi
Abstract: The present invention relates to the microRNA miR-126 and to inhibitors of miR-126 that regulate angiogenesis. The present invention provides compositions and methods for the inhibition of miR-126 and for the inhibition of angiogenesis in vivo.
Type:
Grant
Filed:
April 7, 2009
Date of Patent:
November 10, 2015
Assignee:
CORNELL RESEARCH FOUNDATION, INC.
Inventors:
Mariana Lagos-Quintana, Shahin Rafii, Sai H. Chavala
Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.
Type:
Grant
Filed:
November 6, 2014
Date of Patent:
November 3, 2015
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Yung-Fu Chang, Raghavan U. M Palaniappan